

Pa Shun International Holdings Limited 百信國際控股有限公司

(Incorporated in the Cayman Islands with limited liability) Stock Code: 574



REPORTING PERIOD AND FRAMEWORK

This section, Environmental, Social and Governance ("ESG") Report of Pa Shun International Holdings Limited ("Pa Shun", "Company", "we" and "our"), and its subsidiaries (collectively, the "Group"), presents and disclose ESG related matters that are relevant to the Group's business and have material impacts on the environment and society for the year ended 31 December 2021 (the "Reporting Period"). Unless otherwise stated, the Reporting Period is from 1 January 2021 to 31 December 2021.

This ESG report of the Group has been prepared in compliance with the "Environmental, Social and Governance Reporting Guide" set forth in Appendix 27 to the Rules Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited which was effective during the Reporting Period and based on actual conditions of the Company.

We have identified relevant ESG issues and assess their materiality on our businesses as well as on our stakeholders, through reviewing our operations and holding internal discussions. Adhering to the reporting principles of materiality, quantitative, balance and consistency, this report aims at sharing our performance in aspect of sustainable development and summarising our efforts made on sustainability for the year ended 31 December 2021. Our reporting boundary covers our three major businesses: pharmaceutical distribution, self-operated retail pharmacies and pharmaceutical manufacturing, and includes our following operating entities:

- Chengdu Kexun Pharmaceutical Company Limited
- Chengdu Pashun Pharmacy Chain Store Company Limited
- Chengdu Toyot Pa Shun Pharmacy Company Limited

OUR BUSINESS AND APPROACH TO ESG AND ESG REPORTING

Pa Shun International Holdings Limited ("Pa Shun International", the "Company" or "We") is an investment holding company incorporated in the Cayman Islands, its subsidiaries of which are mainly engaged in pharmaceutical business. We operate under three major segments, including pharmaceutical distribution, self-operated retail pharmacies and pharmaceutical manufacturing. The pharmaceutical distribution segment distributes pharmaceuticals to wholesalers, retail pharmacy stores, hospitals and other medical institutions. The self-operated retail pharmacies segment mainly sells pharmaceutical and healthcare products, cosmetic products and daily necessities in self-operated retail pharmacies. The pharmaceutical manufacturing segment sells pharmaceutical products manufactured by the Company.

For further information about the Group's principal business, it is disclosed in the sub-section headed "Business Review" under the section "Management Discussion and Analysis" in the 2021 annual report.

SUSTAINABLE DEVELOPMENT GOVERNANCE

We implement various sustainable development strategies to make the best use of the valuable natural resources as well as reducing emissions, and develop our business while considering the environmental and social impact at the same time. Under the leadership of an experienced and dedicated management team, we will continue to implement the following sustainable development strategies to maintain high growth and return while undertaking social responsibility. The following are our four major sustainability priorities:



STAKEHOLDER ENGAGEMENT

Our stakeholders come from different sectors, which include shareholders and investors, market regulators, employees, customers, suppliers and business partners, peers and industry associations, and the public to name a few. We gather their opinions through various formal and informal communication methods to fully understand their opinions and expectations for sustainable development purpose, as well as helping us to fulfill our social responsibilities and balance the interests of all stakeholders. We identify the major issues of concern to stakeholders, and set the basis of this Report and the direction of our sustainable development policies according to their feedback, so that our sustainable development direction is closer to their needs and expectations.

STAKEHOLDER ENGAGEMENT (Continued)

During the Reporting Period, we communicated with stakeholders in different means. The communication methods and major issues of their concern are as follows:

Category	Stakeholders	Communication methods	Issues of concern
Internal	Employees	 Conferences Trainings and seminars Cultural and sport activities Intranet and emails Performance appraisals 	 Safeguard the rights and interests of employees Occupational health and safety Working environment Career development opportunities Self-actualization
Internal	Shareholders and investors	 Annual general meeting and other shareholder meetings HKEXnews website, such as annual reports, interim reports and announcements Meeting with investors and analysts Company's website 	 Return on investment Information disclosure and transparency Protection of shareholders' interests and equitable treatment Business risk management
External	Customers	 Marketing and publicity information Company's website Annual reports, interim reports and announcements Emails and customer service hotlines Feedback forms Regular meetings 	 Safe and high-quality products and services Stable relationships Information transparency Integrity Business ethics
External	Suppliers and business partners	 Conferences, phone calls and interviews Regular meetings Reviews and assessments Emails, circulars and manuals Company's website 	 Long-term partnerships Honest cooperation Fairness and openness Information resources sharing Risk reduction
External	Peer and industry associations	Industry conferencesOn-site visits	Experience sharingCooperationFair competitions
External	Market regulators	Information disclosure Reports	 Compliance with laws and regulations Environmental protection Use of resources
External	Public	Voluntary works Charitable and social investments	Community involvementSocial responsibilitiesEmployment promotion

SCOPE OF REPORTING

This report is organized into two sections, namely "Environment" and "Social", focusing on the following in compliance with the ESG standards:

ESG Standard for Reporting		Pa Shun' compliance section	
A. Environment	A1. Emissions	Governance on air and greenhouse gas ("GHG") emissions Waste management	
	A2. Use of resources	Use of resources	
	A3. The environment and natural resources	The environmental impact and natural resources	
	A4. Climate change	Climate change	
B. Social	Employment and labour practices		
	B1. Employment	Employment and labour practices	
	B2. Health and safety	Health and safety	
	B3. Development and training	Development and training	
	B4. Labour standards	Prohibition of child labour and forced labour	
	Operating Practices		
	B5. Supply chain management	Supply chain management	
	B6. Product responsibility	Product responsibility	
	B7. Anti-corruption	Anti-corruption	
	B8. Community investment	Community investment	

CARING FOR THE ENVIRONMENT AND NATURAL RESOURCES

A. ENVIRONMENTAL

A1 Emissions

Governance on Air and Greenhouse Gas ("GHG") Emissions

The Group is strongly committed to the long-term sustainability of the environment and communities in which we operate. As such, the Group has established relevant procedures to detect and prevent any possible pollution incidents which affect the surrounding environment that may occur in the course of our business operations. During the year ended 31 December 2021, we measured and managed our environmental performance in several aspects throughout our operations.

Air emissions

The air emissions generated from our business are immaterial during the Reporting Period. The main source of emission is VOCs generated from fugitive emissions.

Air emissions	2021	Unit
Nitrogen oxidex ("NO _x ")	0	tonne
Sulphur oxidex ("SO _x ")	0	tonne
Particulate matters ("PM")	0	tonne

Greenhouse gas emissions and energy conservation

The greenhouse gas ("GHG") emissions generated by the Group are mainly indirect emissions from electricity consumption during the production activities and office operations. There are also a proportion of direct emissions generated from the use of vehicles. We adopt a series of energy-saving measures (as disclosed under the section headed "Use of Resources") and monitor energy consumption to reduce the production of greenhouse gases and their impact on the environment. The Group targets to reduce greenhouse gas emissions by 10% in the following reporting period.

Our greenhouse gas emissions during the Reporting Period were as follows:

GHG emissions	2021	Unit
Scope 1 – Direct emissions Scope 2 – Energy indirect emissions	88.37 54.94	tCO ₂ e tCO ₂ e
Total emissions	143.31	tCO ₂ e
Intensity (per RMB million revenue)	1.67	tCO ₂ e

A1 Emissions (Continued)

Solid waste

Except our substandard products that are classified as waste drugs, we do not generate hazardous waste¹ during the production process. We entrust qualified recycle services providers to handle hazardous waste for recycling and treatment purposes. The non-hazardous solid waste generated from our business mainly includes dust collected by dust removal equipment, waste PVC, aluminum foil and waste paper boxes from packaging process, as well as food waste from staff canteens, papers and household waste from offices and staff dormitories. Our waste drugs during the Reporting Period were as follows:

	Production/Recovery volume	
Types of hazardous waste	2021	Unit
Waste drugs (HW03)	0.90	tonne
Total emissions	0.90	tonne
Intensity	0.01	tonne/RMB million revenue

We have been committed to reducing waste generation and emissions. We require our employees to reuse or recycle waste as much as possible, handle waste in a responsible manner, and actively reduce unnecessary waste emissions.

The Group has been advocating waste reduction to employees and has established a series of incentive measures to encourage employees to implement the same. These measures include, but not limited to, encourage employees to work and communicate through electronic means and electronic documents, and set up different types of recycling bins to collect recyclable waste. The Group targets to reduce hazardous and non-hazardous waste by 10% in the following reporting period.

The non-hazardous waste² we generated during the Reporting Period was as follows:

Types of Non-hazardous waste	Consumption/production volume 2021 Unit		
Papers Other general waste	6.86 5.50	tonne tonne	
Total	12.36	tonne	
Intensity	0.14	tonne/RMB million revenue	

Refer to hazardous waste as defined in the Directory of National Hazardous Wastes.

Statistics of some of our solid wastes such as dust, waste PVC, aluminum foil and waste paper boxes from the packaging process, as well as food waste from staff canteens are not collected and therefore cannot be disclosed. We will strengthen data collection system in the future and make such disclosure when feasible.

A1 Emissions (Continued)

Sewage

Our sewage discharge includes small amount of production waste water and household sewage. The production waste water mainly comes from equipment cleaning and quality inspection waste water.

The household sewage comes from canteens and offices. The sewage is discharged into the septic tank after being neutralized, and then is discharged into the sewage pipe network of the park and then dispose of and discharge by the sewage treatment plant in the park after meeting the "Integrated Wastewater Discharge Standard" GB8978-1996 level III discharge standard. Since our discharge is mainly household sewage and there is no major industrial sewage discharge, there is no relevant discharge data available.

A2 Use of Resources

Energy

We treasure the effective use of resources and are committed to reducing wastage in daily operations. We consume electricity during the production process, provision of customer services and administrative management. Our Chengdu production base and offices are equipped with air conditioning and lighting adjustment systems, which can be set in day or night modes to reduce energy consumption. In addition, to further reduce electricity consumption during administration, we remind all employees to turn off lights and air conditioners before leaving office or meeting rooms to prevent unnecessary electricity consumption. We also use energy efficient equipment as much as possible to reduce greenhouse gas emissions and reduce the effect of global climate change.

Our freight logistics and administrative management processes consume non-renewable fuels such as unleaded petrol and diesel. Although our air emissions and energy consumption generated from transportation are not significant, we also remind all employees to avoid all unnecessary business travels and use public transportations to reduce pollution and energy consumption. During the Reporting Period, the Group had complied in all material respects with the relevant laws and regulations on energy use, and our energy consumption during the Reporting Period was as follows:

Types of resources	2021	Unit
Non-renewable fuel Purchased electricity	16,000 458,000	kWh kWh
Total energy consumption	474,000	kWh
Intensity	5,517.20	kWh/RMB million revenue

The Group targets to reduce energy consumption by 10% in the following reporting period, by effectively allocating the use of vehicles, using energy saving lighting equipment as well as ensuring power switch off overnight.

A2 Use of resources (Continued)

Water

Our water consumption mainly comes from the pharmaceutical production business in Chengdu and water consumption in general administration. The water is provided by the municipality. We do not draw water directly from the ecosystem and do not operate business in water-scarce regions, and we did not encounter any difficulties in securing suitable water sources. We minimize unnecessary wastage of water resources in the course of business, including reminding all employees to minimize water usage and reuse wherever possible. The Group targets to reduce water consumption by 10% in the following reporting period. The Group's efficient use of water will help to protect the quality of drinking water in the local communities where it operates and the local residents thereof. Our water consumption during the Reporting Period was as follows:

Types of resources	2021	Unit
Tap Water consumption	10,400	m^3
Intensity	121.05	m³/RMB million revenue

Office paper

In addition to recycling waste paper, we also encourage employees to make full use of both sides of paper, such as using the blank side of waste paper for internal document printing or as draft paper, setting appropriate font sizes, optimizing layout to minimize the number of pages, and setting to print multiple pages per sheet to minimize the usage of office paper. Furthermore, we also recommend our employees to use electronic means for communication to reduce paper usage.

Packaging materials

Our main product, Zhenghonghua embrocation (正紅花油), is packaged in glass bottles, and Ampicillin is packaged in aluminum foil and PVC. The packaging materials also include inner lids, outer lids, labels, instruction manual, small boxes, middle boxes, cartons, sealing glue, packing tapes, etc. The following was the packaging material consumption³ during the Reporting Period:

Types of packaging materials	2021	Unit
Glass Metal Plastic Paper	558 - 15 159	tonne tonne tonne tonne
Total amount of packaging materials	732	tonne
Intensity	8.52	tonne/RMB million revenue

The consumption of packaging materials is estimated based on the output of the products and the weight of each packaging material. The total consumption weight may deviate from actual weight.

A3 The Environment and Natural Resources

We have all along been striving to implement various green measures to reduce the significant negative impact of our business on the environment and natural resources. We hope to achieve our sustainable development vision through the efficient use of resources, reduction of carbon emissions, energy conservation and emission reduction, waste management and pollution prevention.

We regularly review the potential environmental impact of various business segments, including lighting, air-conditioning in offices, shops and warehouses, fuel consumption of distribution fleets, generation of certain hazardous wastes (say, bulb waste) and non-hazardous waste, and chemical products. We also conduct regular checks on the efficient use of energy in our Group's business process, and communicate with suppliers about our expectation of their social responsibility and sustainable development. We also actively implement environmental protection measures such as reduce the use of disposable plastic bags, cut down the use of printing paper and packaging paper, and adopt various energy saving measures such as the use of LED lights.

A4 Climate Change

The Group recognises the importance of identifying climate change risk and developing the related strategies in line with the best practices to mitigate the associated impacts on its business operations. Typhoon and rainy seasons in the south, sandstorms, haze, ice, snow and frost in the north, all of which, may directly affect the construction progress and construction cost of development projects. During 2021, thankfully, the weather and climate of the Company's project sites were reasonably forecasted and relatively ideal as compared with the previous years, which caused no material impact on the Company's business.

CARING FOR THE PEOPLE AND SOCIETY

B. SOCIAL

B1 Employment and Labour Practices

Remuneration and benefits

We attach great importance to the benefits, health and development of staffs, and constantly review the differences of our staff benefits and the market. We implement double day-off to balance the living and work of staffs. In addition to annual leave, sick leave, marriage leave, maternity leave, compensatory leave, bereavement leave and other vacation benefits, we also provide social security insurance, medical insurance, annual physical examination, holiday benefits, catering subsidies and other benefits. We have established a staff evaluation and reward policy, packages as well as a comprehensive staff promotion policy, to provide staffs with competitive remuneration and good opportunities of promotion. We set corresponding evaluation conditions for staffs in different positions, carry out comprehensive job evaluations in terms of work performance, attitude and ability, and conduct periodic evaluations for all staffs in cooperation with discipline, accountability survey or supervisor evaluations to provide them with corresponding incentives and promotion opportunities.

We strictly abide by the labour laws and related regulations in the PRC and Hong Kong, including (among others) the Labour Law of the PRC (《中華人民共和國勞動法》), the Labour Contract Law of the PRC (《中華人民共和國勞動合同法》), the Production Safety Law of the PRC (《中華人民共和國安全生產法》), the Occupational Disease Prevention Law of the PRC (《中華人民共和國職業病防治法》) and the Social Security Law of the PRC (《中華人民共和國社會保障法》). During the Reporting Period, we were not involved in any major non-compliance issues related to remuneration and dismissal, recruitment and promotion, working hours, holidays, equal opportunities, diversity, anti-discrimination and other packages and benefits.

Talent recruitment

Our employment principle is "execution, concentration and accountability". Recruiting talents is the best way to support our sustainable development. We select outstanding talents through internal screening and various recruitment channels, and attract new young people to join through internship program. Our recruitment process is equitable, open and transparent, and the recruitment is evaluated based on objective conditions such as candidates' academic qualifications, working experience, skills, communication skills and personal qualities to prevent gender, race, age or any form of discrimination. We formulate various policies and systems, including but not limited to encouraging staffs to give their opinions, promoting transparency in personnel policies and establishing a complaint mechanism to establish an equal opportunity working environment. As of 31 December 2021, our total number of staffs was 964. The following is our employee composition:

By gender	2021
Male Female	32 62
By employment type	2021

The total number of staffs only included those of Pa Shun Pharmaceutical, Kexun Pharmaceutical and Toyot Pa Shun.

B1 Employment and Labour Practices (Continued)

Talent recruitment (Continued)

By age group	2021
Under 20	0
21–30	5
31–40	22
41–50	45
51–60	19
Over 60	3

All employees mentioned above worked within the PRC region.

Retaining talents

The unavailability for development and promotion prospects are the main reasons for the loss of most talents. To retain talents, we provide staffs with promotion opportunities, commend long-term service staffs and arrange proper trainings so that they can attain self-improvement and development, and then obtain good performance and upstream opportunities to develop together with the Company. Our total number of staff turnover during the Reporting Period was 42, and the turnover rate was as follows:

By gender	2021	
Male Female	53.13 40.32	% %
By age group	2021	
Under 20 21–30 31–40 41–50 51–60	100 63.64 33.33 42.11	% % % %

All employees mentioned above worked within the PRC region.

Note: The turnover rate of each group is calculated by dividing the turnover number of the group during the Reporting Period by the number of the employee in the group as at 31 December 2021.

Equal opportunity and diversity

We are committed to creating a diverse and inclusive working environment to prevent staffs from being discriminated against or harassed. We formulate employment policies strictly in accordance with the Labour Law of the PRC (《中華人民共和國勞動法》) and the Labour Contract Law of the PRC (《中華人民共和國勞動合同法》), and offer equal opportunities in recruitment, training, promotion, re-designation, remuneration, benefits and termination of contracts etc. Staffs are entitled to equal employment opportunities regardless of their age, gender, physical conditions, marital status, family position, race, skin colour, nationality, religion, political connection or sexual orientation.

B2 Health and Safety

We put first priority to staff health and safety and try our best to provide them with a safe working environment. We appoint specific person in charge of staffs' occupational health and safety, who is responsible for identifying staffs' occupational health and safety risks, and checking whether there are potential safety hazards in the office, such as checking whether the installation of electrical equipment meets the safety requirements, whether socket plugs are seriously overloaded, whether wires are aging and corroded, whether anti-static measures are adopted in flammable workplace and whether regular maintenance of electrical equipment are conducted.

Our staffs do not need to perform hazardous tasks such as disposal of hazardous materials/hazardous waste, high-altitude work and heavy machinery operation. During the production process, we require that occupational hazard protection facilities (such as ventilation facilities) must be turned on, and air suction and supply devices and mechanical ventilation facilities shall be repaired and maintained regularly to ensure the normal operation of occupational hazard protection facilities and have the effect of dust prevention and ventilation. We often supervise and inspect, urge workers to wear personal protective gear properly, and arrange regular health checks for staffs. For new recruits, we will conduct code of conduct and orientation trainings, which include explanations of occupational health and safety risks and protective measures. We also conduct group safety trainings annually to promote the awareness of work safety.

We strictly abide by the laws and regulations related to occupational health and safety, including (among others) the National Occupational Hygiene Standard Management Measures (《國家職業衛生標準管理辦法》), the Occupational Hazard Declaration Management Measures at Workplaces (《作業場所職業危害申報管理辦法》), the Occupational Health Inspection Management Regulations (《職業性健康檢查管理規定》), the Provisions on the Scope of Occupational Diseases and Measures for the Treatment of Occupational Disease Patients (《職業病範圍和職業病患者處理辦法的規定》) and the Occupational Disease Prevention and Control Law of the PRC (《中華人民共和國職業病防治法》).

During each of the past three years, including the Reporting Period, we did not have any non-compliance incidents of laws and regulations related to occupational safety, work-related fatalities occurred nor work injuries.

B3 Development and Training

Training is the most effective way to improve the overall quality of employees and enhance the competitiveness of the Company. We provide employees with comprehensive and diversified on-the-job training, including orientation training, pre-job training, company annual trainings, team building activities, etc. Those trainings not only fulfill the needs of our operation and development, and also improve staff work efficiency, enabling them to receive positive development, enhance team stability and increase the sense of belonging of staffs. We will also follow up the training results and work performance of staffs to continuously understand their training needs. During the Reporting Period, 96% of our staffs had received trainings with average training hours of 2.22 hours. The details are as follows:

	2021 Percentage of		
By gender	employee trained	Average training hours	
Male Female		137.10 Hours 74.40 Hours	
		2021	
		2021	
By employee category	Percentage of employee trained	2021 Average training hours	

B4 Labor Standards

Prohibition of child labour and forced labour

We do not tolerate any child labour and forced labour and are strictly abide by the national laws on the prevention of child labour and forced labour to avoid the misuse of child labour or forced labour. We also require suppliers not to use child labour or forced labour. Once any relevant behavior is discovered within the Company or suppliers, we will investigate the same seriously. During the Reporting Period, we were not aware of any non-compliance related to child labour or forced labour.

B5 Supply Chain Management

We work closely with various suppliers to jointly maintain the sustainable development of the environment and the society. The supply chain management is a very important part of the environment, social and governance. We need to maintain a stringent standard to ensure that the suppliers we work with are sharing the same vision on sustainable development with us. For example, in order to select the best products, we choose to purchase from suppliers who have their own farms, so as to ensure quality. When selecting suppliers, we will conduct background checks on potential suppliers and take into consideration their business scale, reputation, output and quality and financial strengths to ensure stable product quality, and to ensure customers can enjoy healthy and safe products.

When selecting suppliers, we will choose suppliers in those cities where our businesses are located. During the Reporting Period, we had a total of 197 qualified suppliers located in difference provinces in the PRC.

B6 Product Responsibility

We hold the Good Manufacturing Practice (GMP) and Good Supply Practice (GSP) certificates, and always adhere to the requirements of these practices. The GMP practice has stringent requirements on pharmaceutical equipment, production processes, quality management and testing systems, while the GSP practice requires us to establish control procedures that strictly control all possible quality incidents during the pharmaceutical commodities circulation process to guarantee the quality of pharmaceutical commodities fundamentally. Therefore, we are extremely rigorous in all aspects including, but not limited to, raw materials, staff, facilities and equipment, production process, packaging, quality control and transportation, and have developed a series of quality control systems to ensure that all pharmaceuticals before shipment have passed safety inspections including label review, product compliance, and sampling inspections, so as to ensure that the relevant hygiene and quality requirements have been achieved. In addition, we continue to improve the environmental sanitation of our production bases, with an aim to identify and improve problems in time, while our stores must also hold a necessary business registration certificate, and pass the basic assessment standards such as safety and hygiene.

Our quality inspection personnel are professional and rigorous, and often receive various on-the-job training. All our pharmaceuticals have passed quality inspections, including supplier, product name, specification, prescription, quantity, production date, production batch number, expiry date, country of origin, and various evaluations and inspections such as product certificates and production plant testing reports, so as to ensure that we possess the relevant registered pharmaceutical certificates for all our products. We also provide regular physical examinations and corresponding health advices for our employees to ensure that they are in good health conditions.

All our products are stored appropriately in storage warehouses which are equipped with temperature and humidity control systems pursuant to different categories. Different categories of pharmaceuticals are stored separately, and are arranged to be sold based on production date according to batch number and label. Warehouses are also cleaned and disinfected regularly. Staff who are entering and leaving pharmaceutical warehouses also need to register for entry and exit to ensure products in the warehouses are not exposed to any unnecessary damage.

During the Reporting Period, we have complied with the requirements of Good Manufacturing Practice (GMP) and Good Supply Practice (GSP), as well as the Laws on the Administration of Drugs of the PRC (中華人民共和國藥品管理法), Implementation Ordinance of the Law of the PRC on the Administration of Drugs (中華人民共和國藥品管理法實施條例), the Rules of Good Manufacturing Practice for Drugs (藥品生產品質管制規範), Measures for Production Supervision and Management of Drugs (藥品生產監督管理辦法), Measures for Administration of Drug Recall (藥品召回管理辦法), the Pharmacopoeia of the PRC (中國藥典), the Law on the Administration of Pharmaceuticals (藥品管理法), Good Supply Practice (GSP) (藥品經營品質管制規範(GSP)), Regulation on the Administration of Distribution of Pharmaceutical Products (藥品流通監督管理辦法), the Administrative Measures for the Authorization of Pharmaceutical Business (藥品經營授權管理辦法) and other laws and regulations, and there was no case of recall due to safety and health reasons in the total number of products sold or shipped.

B6 Product Responsibility (Continued)

Intellectual Property and Customer's Privacy

We attach importance to the protection of intellectual property rights, and have established a system to protect intellectual property rights and data confidentiality, and strive to maintain and implement relevant measures to protect intellectual property rights. During the course of our business, we may handle the personal data of customers. We have established a privacy policy for consumer packaging and mailing to ensure that the rights and interests of customers are strictly protected. We will treat all customer's personal information as confidential information and keep the information confidential in accordance with our internal privacy policy to prevent unauthorized access. We also often emphasize on the importance of confidentiality and the legal consequences of violations to our employees, conclude confidentiality agreements with employees, and enhance employees' awareness of protecting intellectual property rights and customer privacy through internal training.

B7 Anti-Corruption

We value and promote the value of ethics and integrity, and will never tolerate any form of bribery, blackmail, fraud and money laundering. We have established a comprehensive monitoring and whistle-blowing mechanism, including telephone hotline reporting numbers and email, etc. We follow up complaints in relation to ethics and integrity seriously and investigate suspicious cases thoroughly. Together with the internal audit function, we form a platform for monitoring misconduct, and implement anti-corruption and misconduct work comprehensively. During the Reporting Period, we strictly abide by the Anti-Money Laundering Law of the PRC (中華人民共和國反洗錢法) and other laws and regulations on anti-corruption, bribery, extortion, fraud and money laundering in Hong Kong and PRC, and have not identified any reports or cases of violations of laws and regulations. We prevent corruption cases strictly from top to bottom, and require managers at all levels to take the lead in ensuring the implementation of anti-corruption and upholding integrity, implement the anti-corruption and upholding integrity policy in an institutionalized manner, and always maintain maximum inspection efforts. We have set up standards for accommodation, transportation, catering and interaction of employees and accompanying persons. The scale, time, quantity and funding of conference activities are also reasonably controlled to prevent the improper use of the relevant reimbursement system. Unless approved by the board of directors of the Company in advance, we prohibit employees from using facilitation fees under non-special circumstances. The contracts with agents, third-party representatives and joint venture partners also include provisions to prevent corruption to reduce the risk of potential illegal payments.

B8 Community Investment

We pay back to the society through continuous participation in various community activities, and let employees to participate in the local community organizations and activities through encouraging employees to participate in and coordinate the solution of community and sub-district labour needs, and actively promote community environment, cultural and sports activities, and achieve mutually beneficial solutions, with an aim to contribute to social harmony and sustainable development.